NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September:
A webcast replay will be available following the conferences and may be accessed on the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.
Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Company Ranked in the Top 35% of All Rated Companies Underscoring the Company's Commitment to…
COLUMBUS, Ohio, March 19, 2025 /PRNewswire/ -- Computed Tomography (CT) scanning, once primarily associated with medical…
PUNE, India, March 19, 2025 /PRNewswire/ -- Tech Mahindra (NSE: TECHM), a leading global provider…
SAN JOSE, Calif., March 19, 2025 /PRNewswire/ -- LEADOPTIK Inc., a Silicon Valley-based medical imaging…
NEW YORK and TOKYO, March 19, 2025 /PRNewswire/ -- Mediagene Inc., a group company of…
New product launches drive double-digit growth in key markets and deliver market outperformance amid economic…